194 related articles for article (PubMed ID: 21788463)
1. Cyclopropavir inhibits the normal function of the human cytomegalovirus UL97 kinase.
James SH; Hartline CB; Harden EA; Driebe EM; Schupp JM; Engelthaler DM; Keim PS; Bowlin TL; Kern ER; Prichard MN
Antimicrob Agents Chemother; 2011 Oct; 55(10):4682-91. PubMed ID: 21788463
[TBL] [Abstract][Full Text] [Related]
2. Cytomegalovirus UL97 kinase catalytic domain mutations that confer multidrug resistance.
Chou S; Ercolani RJ; Marousek G; Bowlin TL
Antimicrob Agents Chemother; 2013 Jul; 57(7):3375-9. PubMed ID: 23650173
[TBL] [Abstract][Full Text] [Related]
3. Cytomegalovirus UL97 mutations in the era of ganciclovir and maribavir.
Chou S
Rev Med Virol; 2008; 18(4):233-46. PubMed ID: 18383425
[TBL] [Abstract][Full Text] [Related]
4. Diverse cytomegalovirus UL27 mutations adapt to loss of viral UL97 kinase activity under maribavir.
Chou S
Antimicrob Agents Chemother; 2009 Jan; 53(1):81-5. PubMed ID: 18981262
[TBL] [Abstract][Full Text] [Related]
5. Cytomegalovirus UL97 kinase mutations that confer maribavir resistance.
Chou S; Wechel LC; Marousek GI
J Infect Dis; 2007 Jul; 196(1):91-4. PubMed ID: 17538888
[TBL] [Abstract][Full Text] [Related]
6. Resistance of human cytomegalovirus to cyclopropavir maps to a base pair deletion in the open reading frame of UL97.
Gentry BG; Vollmer LE; Hall ED; Borysko KZ; Zemlicka J; Kamil JP; Drach JC
Antimicrob Agents Chemother; 2013 Sep; 57(9):4343-8. PubMed ID: 23817384
[TBL] [Abstract][Full Text] [Related]
7. Cyclopropavir susceptibility of cytomegalovirus DNA polymerase mutants selected after antiviral drug exposure.
Chou S; Marousek G; Bowlin TL
Antimicrob Agents Chemother; 2012 Jan; 56(1):197-201. PubMed ID: 21968367
[TBL] [Abstract][Full Text] [Related]
8. Maribavir sensitivity of cytomegalovirus isolates resistant to ganciclovir, cidofovir or foscarnet.
Drew WL; Miner RC; Marousek GI; Chou S
J Clin Virol; 2006 Oct; 37(2):124-7. PubMed ID: 16962820
[TBL] [Abstract][Full Text] [Related]
9. Cytomegalovirus UL97 mutations affecting cyclopropavir and ganciclovir susceptibility.
Chou S; Bowlin TL
Antimicrob Agents Chemother; 2011 Jan; 55(1):382-4. PubMed ID: 21041510
[TBL] [Abstract][Full Text] [Related]
10. Effects on maribavir susceptibility of cytomegalovirus UL97 kinase ATP binding region mutations detected after drug exposure in vitro and in vivo.
Chou S; Hakki M; Villano S
Antiviral Res; 2012 Aug; 95(2):88-92. PubMed ID: 22664236
[TBL] [Abstract][Full Text] [Related]
11. Synthesis and antiviral activities of methylenecyclopropane analogs with 6-alkoxy and 6-alkylthio substitutions that exhibit broad-spectrum antiviral activity against human herpesviruses.
Prichard MN; Williams JD; Komazin-Meredith G; Khan AR; Price NB; Jefferson GM; Harden EA; Hartline CB; Peet NP; Bowlin TL
Antimicrob Agents Chemother; 2013 Aug; 57(8):3518-27. PubMed ID: 23669381
[TBL] [Abstract][Full Text] [Related]
12. Accelerated evolution of maribavir resistance in a cytomegalovirus exonuclease domain II mutant.
Chou S; Marousek GI
J Virol; 2008 Jan; 82(1):246-53. PubMed ID: 17942550
[TBL] [Abstract][Full Text] [Related]
13. Mutations in the human cytomegalovirus UL27 gene that confer resistance to maribavir.
Chou S; Marousek GI; Senters AE; Davis MG; Biron KK
J Virol; 2004 Jul; 78(13):7124-30. PubMed ID: 15194788
[TBL] [Abstract][Full Text] [Related]
14. Expression of the human cytomegalovirus UL97 gene in a chimeric guinea pig cytomegalovirus (GPCMV) results in viable virus with increased susceptibility to ganciclovir and maribavir.
McGregor A; Choi KY; Cui X; McVoy MA; Schleiss MR
Antiviral Res; 2008 Jun; 78(3):250-9. PubMed ID: 18325607
[TBL] [Abstract][Full Text] [Related]
15. Genotypic characterization of human cytomegalovirus UL97 phosphotransferase natural polymorphism in the era of ganciclovir and maribavir.
Boutolleau D; Burrel S; Agut H
Antiviral Res; 2011 Jul; 91(1):32-5. PubMed ID: 21570426
[TBL] [Abstract][Full Text] [Related]
16. Potency and Stereoselectivity of Cyclopropavir Triphosphate Action on Human Cytomegalovirus DNA Polymerase.
Chen H; Li C; Zemlicka J; Gentry BG; Bowlin TL; Coen DM
Antimicrob Agents Chemother; 2016 Jul; 60(7):4176-82. PubMed ID: 27139481
[TBL] [Abstract][Full Text] [Related]
17. Ganciclovir and maribavir susceptibility phenotypes of cytomegalovirus UL97 ATP binding region mutations detected by expanded genotypic testing.
Chou S; Watters M; Sinha R; Kleiboeker S
Antiviral Res; 2021 Sep; 193():105139. PubMed ID: 34273445
[TBL] [Abstract][Full Text] [Related]
18. Rapid semiquantitative real-time PCR for the detection of human cytomegalovirus UL97 mutations conferring ganciclovir resistance.
Göhring K; Mikeler E; Jahn G; Rohde F; Hamprecht K
Antivir Ther; 2008; 13(3):461-6. PubMed ID: 18572760
[TBL] [Abstract][Full Text] [Related]
19. In vitro evaluation of current and novel antivirals in combination against human cytomegalovirus.
O'Brien MS; Markovich KC; Selleseth D; DeVita AV; Sethna P; Gentry BG
Antiviral Res; 2018 Oct; 158():255-263. PubMed ID: 30153445
[TBL] [Abstract][Full Text] [Related]
20. Acyclovir is phosphorylated by the human cytomegalovirus UL97 protein.
Talarico CL; Burnette TC; Miller WH; Smith SL; Davis MG; Stanat SC; Ng TI; He Z; Coen DM; Roizman B; Biron KK
Antimicrob Agents Chemother; 1999 Aug; 43(8):1941-6. PubMed ID: 10428917
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
